3,664 reports of this reaction
8.1% of all PALIPERIDONE reports
#2 most reported adverse reaction
GYNAECOMASTIA is the #2 most commonly reported adverse reaction for PALIPERIDONE, manufactured by Janssen Pharmaceuticals, Inc.. There are 3,664 FDA adverse event reports linking PALIPERIDONE to GYNAECOMASTIA. This represents approximately 8.1% of all 45,344 adverse event reports for this drug.
Patients taking PALIPERIDONE who experience gynaecomastia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GYNAECOMASTIA is moderately reported among PALIPERIDONE users, representing a notable but not dominant share of adverse events.
In addition to gynaecomastia, the following adverse reactions have been reported for PALIPERIDONE:
The following drugs have also been linked to gynaecomastia in FDA adverse event reports:
GYNAECOMASTIA has been reported as an adverse event in 3,664 FDA reports for PALIPERIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GYNAECOMASTIA accounts for approximately 8.1% of all adverse event reports for PALIPERIDONE, making it one of the most commonly reported side effect.
If you experience gynaecomastia while taking PALIPERIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.